Lilly launches $4.5bn medicine foundry to reshape drug production and clinical trials
Eli Lilly and Company has committed $4.5 billion to establish a revolutionary facility in Lebanon, Indiana—the Lilly Medicine Foundry. This one-of-a-kind site is set to ... Read More
Eli Lilly’s once-weekly insulin efsitora alfa matches daily insulin for A1C reduction, boosts stock interest
Eli Lilly and Company (NYSE: LLY) announced results from its QWINT-5 phase 3 trial, demonstrating that its once-weekly insulin efsitora alfa offers a comparable reduction ... Read More
Organon and Eli Lilly expand global reach of migraine treatment Emgality
Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into 11 additional markets, reinforcing their commitment to ... Read More
This diabetes breakthrough drug slashes risk by 94%—discover how tirzepatide is transforming obesity treatment
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide (branded as Zepbound and Mounjaro) dramatically cuts ... Read More
Eli Lilly and OpenAI forge pioneering alliance to combat antimicrobial resistance
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with OpenAI to harness generative AI for the discovery of new antimicrobials, aiming to ... Read More
Lilly to expand Indiana facility with record $5.3bn investment to boost production of APIs
In a historic move for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has announced a staggering $5.3 billion expansion of its Lebanon, Indiana ... Read More
Akouos AK-OTOF yields positive results in hearing restoration Phase 1/2 study
In a significant advancement for medical science and hearing loss treatment, Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), has ... Read More
Eli Lilly and Company completes $1.4bn acquisition of POINT Biopharma
Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a notable ... Read More
Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024
In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE: LLY) has revealed plans to inaugurate its ... Read More
Lilly bags Zepbound FDA approval for obesity treatment
The U.S. Food and Drug Administration has granted approval to Eli Lilly's Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP ... Read More